Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland
March 05 2024 - 6:00AM
Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a clinical-stage
biotechnology company pioneering mRNA cell therapy for autoimmune
diseases, today announced its plans to transition its corporate
headquarters to Frederick, Maryland. The approximately 20,000
square foot state-of-the-art current good manufacturing practice
(cGMP) compliant facility has clinical and commercial manufacturing
scale capabilities designed to support the Company's maturing
pipeline of innovative mRNA cell therapies for the treatment of
autoimmune diseases.
“Our new headquarters and manufacturing facility
will provide us with the infrastructure to support our next phase
of growth while allowing us to remain in the vibrant I-270 Biotech
Corridor community,” said Carsten Brunn, Ph.D., President and Chief
Executive Officer of Cartesian. “Importantly, we believe the new
facility will allow us to scale our wholly-owned, in-house cGMP
manufacturing capabilities for late-stage clinical and commercial
supply of our mRNA cell therapy product candidates, while
continuing to maintain control over product quality and production.
We look forward to relocating to Frederick as we continue to work
toward our mission of expanding the reach of cell therapy to
patients with autoimmune diseases.”
Cartesian’s internally manufactured portfolio of
mRNA cell therapies is purposefully designed to expand the reach of
cell therapy to autoimmunity with product candidates that have the
potential to be administered conveniently and safely in an
outpatient setting without lymphodepletion chemotherapy. Topline
data from the Phase 2b study of Descartes-08 in myasthenia gravis
(MG) is expected in mid-2024. This is the first randomized
placebo-controlled trial of cell therapy in autoimmunity.
About Cartesian
Therapeutics
Cartesian Therapeutics is a clinical-stage
company pioneering mRNA cell therapies for the treatment of
autoimmune diseases. The Company’s lead asset, Descartes-08, is a
potential first-in-class mRNA CAR-T in Phase 2b clinical
development for patients with generalized myasthenia gravis.
Additional Phase 2 studies are planned in systemic lupus
erythematosus under an allowed IND, as well as basket trials in
additional autoimmune indications. The Company’s clinical-stage
pipeline also includes Descartes-15, a next-generation, autologous
anti-BCMA mRNA CAR-T. For more information, please visit
www.cartesiantherapeutics.com or follow the Company on LinkedIn or
X, formerly known as Twitter.
Forward Looking Statements
Any statements in this press release about the
future expectations, plans and prospects of the Company, including
without limitation, statements regarding the Company’s headquarters
relocation, the Company’s manufacturing capabilities and ability to
supply necessary quantities of its product candidates for clinical
trials and potential commercialization, the Company’s ability to
maintain control over its product quality and production, the
potential of Descartes-08 and Descartes-15 and the Company’s other
product candidates to treat myasthenia gravis, systemic lupus
erythematosus, or any other disease, the anticipated timing or the
outcome of ongoing and planned clinical trials, studies and data
readouts, the anticipated timing or the outcome of the FDA’s review
of the Company’s regulatory filings, the Company’s ability to
conduct its clinical trials and preclinical studies, the timing or
making of any regulatory filings, and other statements containing
the words “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “target,” “would,” and similar
expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including, but not limited to, the following: the
uncertainties inherent in the initiation, completion and cost of
clinical trials including proof of concept trials, including
uncertain outcomes, the availability and timing of data from
ongoing and future clinical trials and the results of such trials,
whether preliminary results from a particular clinical trial will
be predictive of the final results of that trial and whether
results of early clinical trials will be indicative of the results
of later clinical trials, the ability to predict results of studies
performed on human beings based on results of studies performed on
non-human subjects, the unproven approach of the Company’s RNA
Armory® technology, potential delays in enrollment of patients,
undesirable side effects of the Company’s product candidates, its
reliance on third parties to conduct its clinical trials, the
Company’s inability to maintain its existing or future
collaborations, licenses or contractual relationships, its
inability to protect its proprietary technology and intellectual
property, potential delays in regulatory approvals, the
availability of funding sufficient for its foreseeable and
unforeseeable operating expenses and capital expenditure
requirements, the Company’s recurring losses from operations and
negative cash flows, substantial fluctuation in the price of the
Company’s common stock, risks related to geopolitical conflicts and
pandemics and other important factors discussed in the “Risk
Factors” section of the Company’s most recent Annual Report on Form
10-K and Quarterly Reports on Form 10-Q, and in other filings that
the Company makes with the Securities and Exchange Commission. In
addition, any forward-looking statements included in this press
release represent the Company’s views only as of the date of its
publication and should not be relied upon as representing its views
as of any subsequent date. The Company specifically disclaims any
intention to update any forward-looking statements included in this
press release, except as required by law.
Contact Information:
Investor Relations:Melissa ForstArgot
Partnerscartesian@argotpartners.com
Media:David RosenArgot
Partnersdavid.rosen@argotpartners.com
Cartesian Therapeutics (NASDAQ:RNAC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cartesian Therapeutics (NASDAQ:RNAC)
Historical Stock Chart
From Sep 2023 to Sep 2024